The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells

BMC Complementary and Alternative Medicine

Tobias Kiesslich⁴  Frieder Berr⁴  Romana Illig¹  Martin Jakab⁵  Martin Pichler³  Daniel Neureiter¹  Andrej Wagner²  Christian Mayr⁴ 

[1] Institute of Pathology, Salzburger Landeskliniken – SALK, Paracelsus Medical University, Salzburg, Austria;Department of Internal Medicine I, Salzburger Landeskliniken – SALK, Paracelsus Medical University, Salzburg, Austria;Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Laboratory for Tumour Biology and Experimental Therapies, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria;Laboratory for Functional and Molecular Membrane Physiology, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria

关键词: Cell cycle arrest;    Cisplatin;    Drug synergism;    Biliary tract cancer;    Green tea;    EGCG;   

Others  :  1217045
DOI  :  10.1186/s12906-015-0721-5

 received in 2015-04-03, accepted in 2015-06-12,  发布年份 2015

【 摘 要 】

Background

The green tea catechin epigallocatechin gallate (EGCG) was shown to effectively inhibit tumor growth in various types of cancer including biliary tract cancer (BTC). For most BTC patients only palliative therapy is possible, leading to a median survival of about one year. Chemoresistance is a major problem that contributes to the high mortality rates of BTC. The aim of this study was to investigate the cytotoxic effect of EGCG alone or in combination with cisplatin on eight BTC cell lines and to investigate the cellular anti-cancer mechanisms of EGCG.

Methods

The effect of EGCG treatment alone or in combination with the standard chemotherapeutic cisplatin on cell viability was analyzed in eight BTC cell lines. Additionally, we analyzed the effects of EGCG on caspase activity, cell cycle distribution and gene expression in the BTC cell line TFK-1.

Results

EGCG significantly reduced cell viability in all eight BTC cell lines (p < 0.05 or p < 0.01, respectively, for most cell lines and EGCG concentrations > 5 μM). Combined EGCG and cisplatin treatment showed a synergistic cytotoxic effect in five cell lines and an antagonistic effect in two cell lines. Furthermore, EGCG reduced the mRNA levels of various cell cycle-related genes, while increasing the expression of the cell cycle inhibitor p21 and the apoptosis-related death receptor 5 (p < 0.05). This observation was accompanied by an increase in caspase activity and cells in the sub-G1 phase of the cell cycle, indicating induction of apoptosis. EGCG also induced a down-regulation of expression of stem cell-related genes and genes that are associated with an aggressive clinical character of the tumor, such as cd133 and abcg2.

Conclusions

EGCG shows various anti-cancer effects in BTC cell lines and might therefore be a potential anticancer drug for future studies in BTC. Additionally, EGCG displays a synergistic cytotoxic effect with cisplatin in most tested BTC cell lines.

【 授权许可】

   
2015 Mayr et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013; 145(6):1215-29.
• [2]Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al.. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81.
• [3]Patel T. Cholangiocarcinoma–controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011; 8(4):189-200.
• [4]Hu G, Zhang L, Rong Y, Ni X, Sun Y. Downstream carcinogenesis signaling pathways by green tea polyphenols: a translational perspective of chemoprevention and treatment for cancers. Curr Drug Metab. 2014; 15(1):14-22.
• [5]Fujiki H, Sueoka E, Watanabe T, Suganuma M. Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds. J Cancer Res Clin Oncol. 2014.
• [6]Du GJ, Zhang Z, Wen XD, Yu C, Calway T, Yuan CS et al.. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 2012; 4(11):1679-91.
• [7]Kim KC, Lee C. Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells. Korean J Physiol Pharmacol. 2014; 18(1):61-6.
• [8]Hagen RM, Chedea VS, Mintoff CP, Bowler E, Morse HR, Ladomery MR. Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells. Int J Oncol. 2013; 43(1):194-200.
• [9]Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol. 2000; 164(1):82-90.
• [10]Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys. 2003; 410(1):177-85.
• [11]Lee SH, Nam HJ, Kang HJ, Kwon HW, Lim YC. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur J Cancer. 2013; 49(15):3210-8.
• [12]Abou El Naga RN, Azab SS. El-Demerdash E, Shaarawy S, El-Merzabani M, Ammar el SM. Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals. Life Sci. 2013; 92(10):555-61.
• [13]Takada M, Ku Y, Habara K, Ajiki T, Suzuki Y, Kuroda Y. Inhibitory effect of epigallocatechin-3-gallate on growth and invasion in human biliary tract carcinoma cells. World J Surg. 2002; 26(6):683-6.
• [14]Senggunprai L, Kukongviriyapan V, Prawan A, Kukongviriyapan U. Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via suppression of JAK/STAT signaling pathway. Phytother Res. 2014; 28(6):841-8.
• [15]Lang M, Henson R, Braconi C, Patel T. Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int. 2009; 29(5):670-7.
• [16]Kwak TW, Kim Do H, Chung CW, Lee HM, Kim CH, Jeong YI et al.. Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells. Evid Based Complement Alternat Med. 2013; 2013:185158.
• [17]Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S et al.. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer. 1992; 52(2):252-60.
• [18]Oertel M, Schastak SI, Tannapfel A, Hermann R, Sack U, Mossner J et al.. Novel bacteriochlorine for high tissue-penetration: photodynamic properties in human biliary tract cancer cells in vitro and in a mouse tumour model. J Photochem Photobiol B. 2003; 71(1-3):1-10.
• [19]Scherdin G, Garbrecht MMK. In vitro interaction of a-difluoromethylornithine (DFMO) and human recombinant interferon-a (rIFN-a) on human cancer cell lines. Immunobiology. 1987; 175:1-143.
• [20]Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D et al.. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol. 1985; 1(6):579-96.
• [21]Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T et al.. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995; 177(1):61-71.
• [22]Purdum PP, Ulissi A, Hylemon PB, Shiffman ML, Moore EW. Cultured human gallbladder epithelia. Methods and partial characterization of a carcinoma-derived model. Lab Invest. 1993; 68(3):345-53.
• [23]Kiesslich T, Alinger B, Wolkersdorfer GW, Ocker M, Neureiter D, Berr F. Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol. 2010; 36(1):49-58.
• [24]Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, Oberdanner C et al.. Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci. 2012; 8(1):15-29.
• [25]de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999; 341(18):1368-78.
• [26]Kiesslich T, Neureiter D, Alinger B, Jansky GL, Berlanda J, Mkrtchyan V et al.. Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochem Photobiol Sci. 2010; 9(5):734-43.
• [27]Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81.
• [28]Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8.
• [29]Stadnisky MD, Quinn J. Flow Cytometry Analysis Automation and Cloud Integration with FlowJo Version 10. Genetic Eng News. 2012; 33(1):38-9.
• [30]Lecumberri E, Dupertuis YM, Miralbell R, Pichard C. Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr. 2013; 32(6):894-903.
• [31]Zhou DH, Wang X, Feng Q. EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. Nutr Cancer. 2014; 66(4):636-44.
• [32]Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO. Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane. J Oncol. 2013; 2013:872957.
• [33]Singh M, Bhui K, Singh R, Shukla Y. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci. 2013; 93(1):7-16.
• [34]Yunos NM, Beale P, Yu JQ, Huq F. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res. 2011; 31(4):1131-40.
• [35]Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012; 31(2):73-99.
• [36]Berridge MJ. Cell Cycle and Proliferation. Cell Signalling Biology. 2012. doi:10.1042/csb0001009
• [37]Iwahashi S, Utsunomiya T, Shimada M, Saito Y, Morine Y, Imura S et al.. High expression of cancer stem cell markers in cholangiolocellular carcinoma. Surg Today. 2013; 43(6):654-60.
• [38]Leelawat K, Keeratichamroen S, Leelawat S, Tohtong R. CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2. Oncol Lett. 2013; 6(5):1439-46.
• [39]Wang M, Xiao J, Shen M, Yahong Y, Tian R, Zhu F et al.. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer. 2011; 128(1):72-81.
• [40]Mayr C, Neureiter D, Wagner A, Pichler M, Kiesslich T. The role of polycomb repressive complexes in biliary tract cancer. Expert Opin Ther Targets. 2014:1-13. doi:10.1517/14728222.2014.986460.
• [41]Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE, Eckert RL. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis. 2011; 32(10):1525-32.